Market Place
News Type
Upload your Marketing & Sales content on your company Virtual Booth, click HERE
X
Developments Immunology Phase III
China 
Details:
The clinical study is a randomized, double-blind, parallel group, active control study to compare the efficacy and safety of BAT2506 to Simponi® in psoriatic arthritis (PsA) patients that is expected to enroll approximately 480 volunteers. In the U.S.,
Lead Product(s): Golimumab
Therapeutic Area: Immunology Product Name: BAT2506
Highest Development Status: Phase III Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 09, 2021
Details:
Biogen will gain exclusive regulatory, manufacturing and commercial rights to BAT1806 in all countries excluding China (including Hong Kong, Macau and Taiwan). Biogen will expand its global biosimilars footprint with the potential approval of BAT1806.
Lead Product(s): BAT1806
Therapeutic Area: Immunology Product Name: BAT1806
Highest Development Status: Phase III Product Type: Large molecule
Partner/Sponsor/Collaborator: Biogen
Deal Size: Undisclosed Upfront Cash: $30.0 million
Deal Type: Agreement April 08, 2021
Details:
The new drug application (NDA) of HLX01 (rituximab injection) for rheumatoid arthritis (RA) is based on results from the Phase 1 clinical study (HLX01-RA01) and Phase 3 clinical study (HLX01-RA03).
Lead Product(s): Rituximab
Therapeutic Area: Immunology Product Name: HLX01
Highest Development Status: Phase III Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 17, 2020
Details:
Tadekinig alfa is a novel IL-18 binding protein in pivotal Phase 3 testing for orphan disease IL-18 driven monogenic Hemophagocytic Lymphohistiocytosis (HLH). WuXi Biologics to undertake commercial scale manufacturing to support U.S. market launch.
Lead Product(s): Tadekinig alfa
Therapeutic Area: Immunology Product Name: r-hIL-18BP
Highest Development Status: Phase III Product Type: Large molecule
Partner/Sponsor/Collaborator: AB2 Bio
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration October 29, 2020
Details:
Funds will support clinical trials and commercialization for its autoimmune, oncology and ophthalmology pipeline.
Lead Product(s): Telitacicept
Therapeutic Area: Immunology Product Name: Undisclosed
Highest Development Status: Phase III Product Type: Large molecule
Partner/Sponsor/Collaborator: Lilly Asia Ventures
Deal Size: $100.0 million Upfront Cash: Undisclosed
Deal Type: Financing April 02, 2020
